SB-649,915

From WikiMD's WELLNESSPEDIA

SB-649,915 is a drug that was developed by GlaxoSmithKline for the treatment of depression. It acts as a potent and selective 5-HT1A receptor antagonist, and has been researched for its potential antidepressant effects.

History[edit]

SB-649,915 was developed by the pharmaceutical company GlaxoSmithKline. It was designed to act as a potent and selective antagonist for the 5-HT1A receptor, a type of serotonin receptor that is often targeted in the treatment of depression and other mood disorders.

Mechanism of Action[edit]

SB-649,915 works by blocking the action of the 5-HT1A receptor. This receptor is one of several that are activated by serotonin, a neurotransmitter that is involved in the regulation of mood, appetite, and sleep. By blocking the action of this receptor, SB-649,915 may help to increase the availability of serotonin in the brain, which could potentially improve symptoms of depression.

Clinical Trials[edit]

While SB-649,915 has been studied in clinical trials, it has not yet been approved for use in the treatment of depression. The results of these trials have not been publicly disclosed, so it is not currently known how effective this drug may be in treating depression or what side effects it may cause.

See Also[edit]

References[edit]


Stub icon

This WikiMD article can only be edited by registered and verified editors. You can log in or register.

  • SB-649,915
    SB-649,915

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=SB-649,915&oldid=6335246"